Autoimmune disease and immune reset

First posted October 14 — NCT07873931. Bristol Myers Squibb registers a 60-person, open-label, single-group Phase 1 study of in-vivo CD19 CAR-T therapy BMS-986553 for refractory lupus/lupus nephritis, inflammatory myopathies, systemic sclerosis, rheumatoid arthritis and Sjögren disease. Primary assessments include dose-limiting toxicity over 28 days and adverse events, serious events and laboratory abnormalities through approximately 90 days.

Status and U.S.: Not yet recruiting; no efficacy or safety results and no approval for these uses. The record does not disclose enough delivery or conditioning detail to call it mRNA-based or chemotherapy-free. This separate protocol does not establish restart of paused ex-vivo CAR-T programs.

Timing: October 30, 2026 start, October 20, 2032 primary completion and January 31, 2033 final completion are registry estimates, not promised readout dates.

Sources: ClinicalTrials.gov · NCT07873931.

October 15 registry updates. NCT07448298 (AFN50, early Phase 1, in-vivo CAR generation using T-cell-targeted lipid nanoparticles containing CAR-encoding RNA) and NCT07361094 (autologous CD19/BCMA dual-target CAR-T, Phase 1, manufactured ex vivo) are both withdrawn, each with zero actual participants and the stated reason “No participants.”

These are different constructs. Neither record supplies a human efficacy result, a toxicity failure or a reason to discontinue the broader platform. Date fields still include an 'actual' start despite zero enrollment; that inconsistency is not evidence of dosing. No U.S. product approval follows from these registrations.

Sources: ClinicalTrials.gov · NCT07448298; ClinicalTrials.gov · NCT07361094.

October 15 registry update — NCT05798117. The uncontrolled Phase 1/2 lupus study of YTB323/rapcabtagene autoleucel now lists completed, 21 actual participants, and actual primary/final completion September 24, 2026. No results are posted.

Completion of this record does not establish resumption of recruitment, clearance of the previously reported autoimmune-program hold, remission, cure or a favorable safety profile. The wider hold remains unresolved in the sources checked. U.S. approval for lupus is not established.

Sources: ClinicalTrials.gov · NCT05798117.

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 35 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved.

Informal-source coverage: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence. Saved Mount Sinai IBD CAR-T planning remains unconfirmed; the new BMS protocol does not confirm that institutional claim.

Full coverage record.

First posted September 17; updated October 13, 2026; newly appraised October 13. AbelZeta’s NCT07825389 plans 119 participants with refractory primary or secondary progressive multiple sclerosis, phase 1b/2, single-arm open-label. Autologous C-CAR168 targets CD20 and BCMA after fludarabine/cyclophosphamide lymphodepletion. Primary assessments include serious/toxic events, CRS and ICANS through month 24, plus six-month confirmed composite disability progression through month 12 in phase 2.

Status/limits/U.S.: Not yet recruiting; no clinical or safety results. Without randomized standard care, disability changes require caution. This is not a verified restart of other companies’ paused CAR-T programs or a demonstrated MS cure. Investigational.

Timing: February 2027 estimated start and February 2030 primary/final completion, month precision. The separate C-CAR168 lupus-nephritis record still says not yet recruiting after an elapsed September 30 start estimate; no enrollment inferred.

Sources: ClinicalTrials.gov · NCT07825389.

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 29 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved. C-CAR168 lupus record remains not yet recruiting after elapsed start; no verified rap-cel/zola-cel restart, full FB102 effect/harms or Mount Sinai IBD initiation.

Informal-source coverage: Revisited original lupus Reddit thread, which repeats prula-cel release and anonymous cross-trial safety predictions. These are not proof of safer platforms. Mehandru IBD planning remains unconfirmed without matched initiation; review literature is not confirmation of the specific Mount Sinai plan.

Full coverage record.

Source date: October 8, 2026. Evidence: sponsor-only topline. FB102-301 (NCT06982963) enrolled 126 symptom-free adults on a strict gluten-free diet for at least twelve months. Randomization was 2:2:1 to two intravenous anti-CD122 doses or placebo during an eight-week gluten challenge. Argenx reports a significant day-78 villus-height/crypt-depth response (p=.0176) and supportive inflammatory/symptom measures, without absolute effect estimates, intervals, dose-specific results or numerical safety tables.

Limits/registry discrepancy: The last registry update, November 18, 2025, still lists 100 estimated participants and the Vh:Cd–IEL composite (VCIEL) as primary, while the release calls Vh:Cd primary. The stale record cannot reconcile endpoint designation or replace the reported 126 with 100. Full protocol/statistical plan is needed. A short controlled challenge does not establish unrestricted dietary tolerance, long-term organ protection or cure.

Safety/U.S./next: “No new safety signals” is a qualitative sponsor statement, not quantified risk. FB102 remains investigational; Fast Track is not approval. Phase 3 is planned. Detailed results are promised at an unspecified meeting, with no firm next date.

Original October 8 release; trial registry.

Source date: October 2, 2026; newly appraised October 9. AMETHYST Part A (NCT05531565) initially evaluated 93 adults with active cutaneous lupus despite or intolerant of antimalarials. In the originally active-treated group, clear/almost-clear skin by the CLA-IGA erythema endpoint rose from 19.0% at week 24 to 27.2% at week 52, and CLASI-70 from 21.7% to 28.8%. The placebo-crossover group reached 33.7% clear/almost-clear skin at week 52.

Design/safety limits: After week 24 all participants received active drug, so these are longitudinal/crossover observations rather than a contemporaneous placebo comparison. Arm-specific evaluable denominators and intervals were not supplied. The extension safety denominator is 88; 3/88 (3.4%) had serious adverse events. Common events included nasopharyngitis, influenza and joint pain. This does not demonstrate cure, reversal of established scars or prevention of systemic disease.

U.S./next: Investigational; Breakthrough Therapy designation is not approval. The randomized phase 3 part remains separate, with results forecast H1 2027. The October 9 registry lists active-not-recruiting, estimated primary completion October 20, 2026; completion is not publication.

October 2 sponsor report; primary registry.

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (28 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; No matched rap-cel/zola-cel restart announcement verified; pre-pause or unchanged recruiting labels do not prove restart. Full CAR-T longer-term safety, ACR abstract census, FB102 protocol and litifilimab arm-level tables remain gaps.

Informal-source coverage: Read original OncLive September22 discussion of Mount Sinai IBD CAR-T planning; no matched newly initiated study verified, existing stable claim remains unconfirmed. Read lupus/scleroderma Reddit anecdotes and discussions; unverified identity, selected responders and unsupported safety rankings mean no comparative or cure result. Full podcast recordings unreviewed.

Full coverage record.

Source date: First posted October 2, 2026; registry-reported actual start September 14. Evidence: NCT07855302, recruiting phase 1 at Seoul National University Hospital.

Eight planned participants up to age 25 with refractory childhood-onset systemic lupus receive a CD19-targeted autologous CAR-T infusion, preceded by protocol-defined lymphodepletion. The primary outcome is lupus low disease activity at one year; renal response is secondary.

Limits/safety: Single-arm early research, no posted outcomes or safety rates. Low disease activity is not cure; lymphodepletion and CAR-T risks require direct follow-up. This does not establish benefit for other autoimmune diseases.

U.S./next milestone: No U.S. authorization established for this construct. Estimated primary/final completion December 2028; public readout date unknown.

Primary registry.

Source/event date: 2026-09-24. Evidence: Sponsor-only uncontrolled clinical follow-up; recovered September event.

Kyverna reported single-arm CD19 CAR-T follow-up in refractory stiff-person syndrome (KYSA-8, NCT06588491; 26 adults) and generalized myasthenia gravis (KYSA-6, NCT06193889; seven patients). In SPS, median timed-25-foot-walk improvement was 49% at 12 months; 92% were off chronic SPS immunotherapies. Only five myasthenia patients had at least one-year follow-up; all seven had week-24 mean MG-ADL and QMG improvements of 8.3 and 11.7 points, and six were off immunosuppression at last follow-up. No high-grade CRS, ICANS or IEC-HS was reported. Selected uncontrolled cohorts do not prove comparative benefit, cure, or rare/long-term safety; lymphodepletion remains part of treatment. Miv-cel is investigational. Sponsor forecasts full SPS results at MS Toronto October 21–23 and rolling SPS BLA completion in Q4 2026. Sponsor.

Next milestone: October 21–23, 2026 — sponsor-announced presentation window for full SPS results. Rolling BLA completion is forecast for Q4 2026.

Sponsor; ClinicalTrials.gov · NCT06588491; ClinicalTrials.gov · NCT06193889.

Source/event date: 2026-09-29. Evidence: Sponsor-reported regulatory filing acceptance.

Genentech reports FDA acceptance and granted Priority Review for oral fenebrutinib in relapsing and primary progressive MS. This is review, not approval. FENhance 1 and 2 reduced annualized relapses versus teriflunomide by 51.1% and 58.5% over 96 weeks. FENtrepid met noninferiority to ocrelizumab for 12-week confirmed composite disability progression (HR 0.88, 95% CI 0.75–1.03); numerical benefit does not establish superiority. Serious adverse events were 9% versus 9% and 11% versus 6% in relapsing trials, and 19% in both progressive-disease arms. Liver-enzyme elevations were more frequent than with ocrelizumab. The sponsor acknowledges a fatality imbalance; detailed attribution needs full evidence review. No FDA action date appears in the announcement. Fenebrutinib remains investigational. Sponsor.

Next milestone: FDA decision after granted Priority Review; action date undisclosed.

Sponsor.

Related findings:

• Olumiant U.S. approval expands to severe alopecia areata from age 12.
• Bempikibart: preliminary hair retention after stopping treatment.

Source date: 2026-09-28. Evidence: Sponsor phase 1 uncontrolled human results.

Adicet reports one-year remissions after donor-derived anti-CD20 gamma-delta CAR-T; the small uncontrolled dataset does not establish cure or comparative safety. August 28 cutoff: 22 efficacy-evaluable participants (16 lupus nephritis, 6 extra-renal SLE), followed 6–21 months. At 12 months, DORIS remission was 7/13 (54%) and complete renal response 5/10 (50%). Participants received cyclophosphamide/fludarabine lymphodepletion. All discontinued immunosuppressants; all but one tapered steroids to ≤5 mg prednisone equivalent. NCT06375993.

Limitations: Changing follow-up denominators; no randomized comparator or confidence intervals. Biomarker reconstitution is not proof of permanent immune reset. Continued low-dose steroids mean this is not uniformly medication-free. Registry remains a March snapshot; estimated enrollment 180 is not the analyzed cohort.

Safety: Among 24 safety-evaluable participants, infections occurred in 13 (54%), grade ≥3 in 2 (8.3%); grade 1/2 CRS in 25%. No observed higher-grade CRS, ICANS, IEC-HS or graft-versus-host disease; rare/late risks remain uncertain.

U.S. status: Investigational; FDA alignment on outpatient study dosing is not marketing approval.

Next milestone: Sponsor forecasts pivotal lupus-nephritis study start-up in Q4 2026; systemic-sclerosis data H1 2027 and LN/SLE update mid-2027. Slides forecast pivotal interim data in 2028 and readout in 2029. Start-up is not enrollment; potential nonrenal expansion needs regulatory alignment.

Adicet September 28 release; Adicet clinical-data slides, pages 6–15; Phase 1 registry.

Source date: 2026-09-17. Event date: 2026-09-15. Evidence: Investigator interim adaptive-trial decision.

The metformin arm stopped September 15; alpha-lipoic acid passed the interim checkpoint and continues to the next stage. The planned interim assessment combined MRI and clinical measures. The investigator team announced the decision September 17; a definitive phase 3 answer for the continuing treatment still requires follow-up.

Limitations: This is progressive-MS evidence, not a healthy-aging or lifespan trial. Numerical comparative effects were not reported in the reviewed summary. Passing the checkpoint does not establish alpha-lipoic acid clinical benefit.

Safety: The stated stopping reason was insufficient benefit; no new quantified safety result was provided.

U.S. status: No new MS or longevity approval.

Next milestone: Ongoing alpha-lipoic acid phase 3 follow-up; no exact result date verified.

OCTOPUS interim decision; Trial participant explanation of stop date.

Source date: 2026-09-23. Event date: 2026-09-23. Evidence: Sponsor topline randomized human trial.

Immunovant stopped IMVT-1402 development for cutaneous lupus after its phase 2 proof-of-concept trial missed the primary endpoint. The global randomized, double-blind, placebo-controlled study enrolled 57 patients. Week-12 percent change in CLASI-A did not achieve statistical significance. Other autoimmune programs continue. Trial: NCT06980805.

Limitations: No effect size, confidence interval or p value disclosed. Numerical trends and IgG associations do not overturn the primary miss. The August 28 registry snapshot remains active-not-recruiting and is stale relative to the discontinuation announcement.

Safety: Sponsor described favorable safety without a quantitative adverse-event table.

U.S. status: Investigational; no U.S. approval for this indication.

Next milestone: CLE development discontinued; full result publication date unknown. Other indications retain separate milestones.

Immunovant CLE topline announcement; ClinicalTrials.gov NCT06980805.

Source date: 2026-09-23. Event date: 2026-09-23. Evidence: Sponsor phase 2a follow-up.

EVERLAST-A reported sustained skin clearance 24 weeks after the second ORKA-001 dose. Among 63 initially active-treated participants, week-28 PASI100 was 45/63 (71.4%), PASI90 55/63 (87.3%), and IGA 0/1 53/63 (84.1%). Doses were 600 mg at weeks 0 and 4. The trial randomized 84 participants 3:1; placebo crossed over at weeks 16 and 20.

Limitations: There is no contemporaneous untreated comparator after crossover. These sponsor data do not establish annual dosing, cure, or long-term safety.

Safety: Weeks 16–28: upper respiratory infections 7/83 (8%); two serious events, tibial fracture and prostate adenocarcinoma, both judged unrelated. No injection-site reactions reported. Safety and efficacy denominators differ.

U.S. status: Investigational; not U.S.-approved.

Next milestone: EVERLAST-A week-52 results forecast December 2026; EVERLAST-B week-16 results forecast Q4 2026.

Oruka EVERLAST-A week-28 release.

Related findings:

• Sefaxersen meets interim IgA-nephropathy proteinuria endpoint.
• Human tissue study investigates persistent CAR-T-associated enterocolitis.

Source date: 2026-09-18. Event date: 2026-09-17. Evidence: Regulator recommendation; opinion September 17, published September 18.

EMA’s CHMP recommends gefurulimab as add-on therapy for adults with AChR-antibody-positive generalized myasthenia gravis. Weekly subcutaneous C5 blockade improved disease severity and daily function in the 26-week placebo-controlled PREVAIL trial. The regulatory opinion adds a development milestone rather than a new efficacy readout.

Limitations: A CHMP opinion precedes a separate European Commission authorization; it does not establish U.S. approval or immune-reset remission.

Safety: EMA lists injection-site reactions, back/joint/muscle symptoms, nausea and vomiting among common effects. The complete approved EU label was not yet available at this check.

U.S. status: No new U.S. authorization verified in this European action.

Next milestone: European Commission decision pending; no dependable date retrieved.

EMA Klygefa record.

Related findings:

• ORIGIN 3 reports kidney-function and progression benefit.
• Ebribafusp advances into a kidney-disease basket trial.
• Bempikibart off-treatment alopecia-areata results scheduled for September 30.

Source date: 2026-09-14. Evidence: Peer-reviewed randomized human trial.

TIME IS MUSCLE supports earlier IVIG add-on in a small newly diagnosed inflammatory-myopathy population. The double-blind trial randomized 44 adults, all treated with high-dose prednisone. The reported primary-outcome sample included 42 participants: 23 receiving IVIG and 19 receiving placebo. At week 12, Total Improvement Score was 60.0 (95% CI 52.6–67.4) versus 42.5 (95% CI 30.6–54.4), p = .01. Moderate improvement occurred in 91% versus 53%. Trial identifier: EudraCT2020-001710-37-NL.

Limitations: This was a single-center study with short follow-up and a disease-specific composite endpoint. It does not establish healthy muscle gain or muscle preservation during GLP-1 treatment. The major-response analysis was post hoc. Full supplemental analyses were not reviewed.

Safety: One asymptomatic deep-vein thrombosis occurred in the IVIG group.

U.S. status: No new U.S. label action established by this publication.

Next milestone: Further comparative evidence and longer follow-up are undated.

JAMA Neurology September14 publication.

Current position: CAR-T has produced striking remission signals in small studies of severe, refractory autoimmune disease, and registrational programs are now underway. The central unanswered question is whether these responses translate into durable clinical benefit with acceptable treatment burden and safety in larger, more representative populations. An immune system becoming repopulated with B cells after treatment is a biological observation; it does not by itself prove that autoimmunity has been permanently eliminated. This watch records disease-specific responses, how long patients remain off other drugs, and the denominator with adequate follow-up.

Academic CD19 CAR-T establishes the proof of concept. A 2024 peer-reviewed case series included 15 heavily pretreated patients: eight with lupus, three with inflammatory myositis and four with systemic sclerosis. Median follow-up was 15 months, with a range of four to 29 months. The study reported lupus remission, major myositis responses, improvement in systemic-sclerosis disease activity, and withdrawal of immunosuppression. Treatment included fludarabine/cyclophosphamide preconditioning. Most cytokine-release events were mild, but grade 2 cytokine-release syndrome, mild neurotoxicity and a pneumonia requiring hospitalization each occurred in one patient. With no randomized comparator, the study cannot quantify benefit relative to current care or reliably estimate rare adverse events. These were refractory patients selected for an intensive intervention, not people with mild disease. NEJM case series.

Resecabtagene autoleucel, rese-cel/formerly CABA-201 — Cabaletta Bio. The lead watch is RESET-Myositis (NCT06154252), an open-label study listed as recruiting in its June 10, 2026 registry update. The registrational cohort includes dermatomyositis and antisynthetase syndrome; the broader study also includes additional myositis cohorts. Its registration and protocol evolution matter because a small single-arm registrational design provides different evidence from a large randomized trial. RESET-Myositis registry.

Cabaletta's August 13, 2026 update forecasts data from the 17-patient registrational adult cohort in mid-2027, with a possible first BLA in the second half of 2027 if successful. These are sponsor targets, not regulatory commitments. The company is also exploring treatment without preconditioning in RESET-SLE (NCT06121297), pemphigus and myasthenia gravis. After early low-dose findings it is advancing higher-dose cohorts; omission of chemotherapy could reduce treatment burden, but must preserve depth and durability of clinical response. The August update does not establish a chemotherapy-free regimen as effective or approved. Manufacturing improvements are operational milestones, not additional evidence of remission. August business update; RESET-SLE identifier and early clinical program.

In vivo CAR-T is now human research, but much earlier. A September 17, 2025 NEJM letter reports generating CD19 CAR-T cells inside patients with refractory lupus using lipid nanoparticles. It describes B-cell depletion and reduced disease activity without major toxic effects in the reported early experience. This supports feasibility, not an established comparative benefit or a reliable estimate of uncommon harms. It is technically and clinically distinct from collecting and modifying a patient's T cells in a factory. Follow larger cohorts, reproducible delivery, immune recovery, redosing, organ-specific outcomes and duration of remission. No firm next readout date was verified, and this baseline does not invent an NCT identifier for the report. Primary human report.

U.S. status and interpretation: the featured autoimmune uses remain investigational in the verified program descriptions. A designation such as RMAT or an FDA-cleared investigational application is not permission to market the therapy. Positive oncology CAR-T experience does not automatically establish an autoimmune indication. Track all serious infections, prolonged cytopenias, hypogammaglobulinemia, retreatment and hospital burden alongside efficacy; short follow-up cannot settle lifetime safety or whether a finite intervention replaces chronic therapy.